treatment is the cornerstone of therapy for acromegaly at our center regardless o and extrasellar expansion, we conducted a retrospective study of the Pituitary Surgery Database of the recently founded Skull Base Surgery Unit of our Center. Our interest was to present the initial results of endoscopic transnasal transsphenoidal surgery (ETSS) at our compare them, in terms biochemical remission in patients with growth hormone (GH) adenomas, to other published series.
PATIENTS AND METHODS
We performed a retrospective analysis of our Pituitary Surgery database, where we identified eleven patients with GH adenomas. These patients had been referred to our Center for neuroendocrinological management, and they underwent ETSS for tumor resection between January 2008 and September 2011. The evaluation was performed with the authorization of the Ethics Committee of our Center, (CLOBI protocol number: CLOBI-HM-027-2011) and informed consent was obtained from all subjects regarding the proposed operation.
The inclusion criteria were the following: diagnosis of acromegaly based on GH levels > 1 ng/mL, insulin-like growth factor (IGF) I levels greater than the normal range for age and sex, and imaging evidence for a pituitary adenoma. Patients must have undergone ETSS at our Center between January 2008 and September 2011 as their primary treatment, and they must have been followed for at least six months by our multidisciplinary team of endocrinologists, neurosurgeons, and ear, nose and throat (ENT) surgeons with laboratory analyses and imaging.
Preoperative endocrinological assessment was performed at our Center by means of radioimmunoassay. A full endocrinological panel was obtained, in order to determine serum GH and IGF-I levels, as well as further hormone deficiencies. If other hormone disorders wer identified, the corresponding treatment was Revista Médica de la Universidad de Costa Rica. Volumen 8, número 2
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We performed a retrospective analysis of database, where we identified eleven patients with GH-secreting adenomas. These patients had been referred to our Center for neuroendocrinological management, and they underwent ETSS for tumor resection between January 2008 and September 2011. The on was performed with the authorization of the Ethics Committee of our Center, (CLOBI 2011) and informed consent was obtained from all subjects
The inclusion criteria were the following: nosis of acromegaly based on GH levels > 1 like growth factor (IGF) I levels greater than the normal range for age and sex, and imaging evidence for a pituitary adenoma. Patients must have undergone ETSS at our Center between d September 2011 as their primary treatment, and they must have been followed for at least six months by our multidisciplinary team of endocrinologists, neurosurgeons, and ear, nose and throat (ENT) surgeons with laboratory analyses and imaging.
ative endocrinological assessment was performed at our Center by means of radioimmunoassay. A full endocrinological panel was obtained, in order to determine serum GH and I levels, as well as further hormone deficiencies. If other hormone disorders were identified, the corresponding treatment was started. In the post-operative period, serum GH and IGF-I were assessed at three The 2009 Acromegaly Consensus Group criteria for cure were used to determine biochemical remission in all of patients with normal IGF and random GH levels lower than 1,0 ng/mL, months after surgery, were considered in biochemical remission. Alternatively, patients with elevated IGF-I levels at three month considered in biochemical remission only if their GH nadir during an oral glucose tolerance test (OGTT), was less than 0,4 ng/mL.
In case that biochemical remission was not achieved, the individual cases were raised to the Board of Directors of Committee of our institution. Each case was analyzed by this Committee in order to determine whether the patient would warrant a somatostatin analogue agent. If the decision was positive, somatostatin analogues were administered and IGF-I and GH levels were measured six months later to assess biochemical remission based on the aforementioned criteria.
All patients were evaluated by an ophthalmologist for visual acuity and visual fields. The latter were assessed through static perimetry. Visual field compromise, such as homonymous hemianopia, bitemporal hemianopia or quadrantanopia, was then correlated to imaging findings.
All patients were also classified according to their comorbidities. Hypertension, dyslipidemia, diabetes mellitus, obstructive sleep apnea, osteoarthritis and cardiovascular disease were sought in these patients in order to assess acromegaly manifestations.
All patients underwent pre radiological evaluation by means of contrast enhanced computed gadolinium-enhanced magnetic resonance imaging (MRI).All pituitary adenomas were classified according to maximum tumor diameter as microadenomas (< 10 olumen 8, número 2, artículo 5 2014
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operative period, serum GH I were assessed at three and six months. The 2009 Acromegaly Consensus Group criteria [3] for cure were used to determine biochemical remission in all of our patients. Accordingly, patients with normal IGF-I levels for age and sex, and random GH levels lower than 1,0 ng/mL, three months after surgery, were considered in biochemical remission. Alternatively, patients with I levels at three months, were considered in biochemical remission only if their GH nadir during an oral glucose tolerance test (OGTT), was less than 0,4 ng/mL.
In case that biochemical remission was not achieved, the individual cases were raised to the Board of Directors of the Pharmacotherapy Committee of our institution. Each case was analyzed by this Committee in order to determine whether the patient would warrant a somatostatin analogue agent. If the decision was positive, somatostatin analogues were administered and I and GH levels were measured six months later to assess biochemical remission based on the aforementioned criteria.
All patients were evaluated by an ophthalmologist for visual acuity and visual fields. The latter were assessed through static perimetry. Visual field compromise, such as homonymous hemianopia, bitemporal hemianopia or quadrantanopia, was then correlated to imaging All patients were also classified according to their comorbidities. Hypertension, dyslipidemia, , obstructive sleep apnea, osteoarthritis and cardiovascular disease were sought in these patients in order to assess acromegaly manifestations.
All patients underwent pre-operatory radiological evaluation by means of contrastenhanced computed tomography (CECT) or enhanced magnetic resonance imaging (MRI).All pituitary adenomas were classified according to maximum tumor diameter as mm) or macroadenomas (> Costa Rica, 2060 San José, Costa Rica. ® All rights reserved. Licensed under a Creative Commons Unported License. Contáctenos: rev.med.ucr@gmail.com 10 mm). They were further classified according to the modified Hardy system considering their extension and invasion. Imaging studies were obtained post-operatively to assess tumor persistence or recurrence.
Because of the resources of our institution, it is possible to perform both pre-operative CECT and MRI, bu post-operative follow-up imaging is mainly performed by means of CECT. Only select cases undergo post-operative MRI because of the availability of these studies in our socioeconomic context.
All
patients underwent endoscopic transnasal transsphenoidal surgery at our Center. An ENT surgeon was responsible for the nasal and sphenoidal phases of the operation, during which the middle turbinate was identified and resected in order to create an adequate surgical pathway. Ethmoidectomies were not routinely performed. An ample sphenoidotomy was completed in all cases, and all the anatomic landmarks inside the sphenoid sinus were explored before proceeding with the adenomectomy.
The sellar phase of the surgery was then performed by a neurosurgeon, who was responsible for the tumor removal. Once the neoplasm was resected, the endoscope was moved forward into the cavity, in order to identify tumor remnants in the recesses created by the descent of the suprasellar cistern. Sellar repair was performed in cases of extended approaches or intraoperative cerebrospinal fluid (CSF) leakage by means of dural substitutes, surgicel®, gelfoam® or fibrin glue. Nasal packing was not routinely performed after the surgery.
Patients were then monitored closely for post-operative complications, such as meningitis, epistaxis, pneumocephalus, CSF leakage, pneumonia and death. Strict measurement of urine output and urinary density were also carried out in order to identify diabetes insipidus. They were further classified according to ied Hardy system considering their extension and invasion. Imaging studies were operatively to assess tumor persistence or recurrence.
Because of the resources of our institution, it is possible to operative CECT and MRI, but the up imaging is mainly performed by means of CECT. Only select cases operative MRI because of the availability of these studies in our socioeconomic All patients underwent endoscopic dal surgery at our Center. An ENT surgeon was responsible for the nasal and sphenoidal phases of the operation, during which the middle turbinate was identified and resected in order to create an adequate surgical pathway. y performed. An ample sphenoidotomy was completed in all cases, and all the anatomic landmarks inside the sphenoid sinus were explored before proceeding
The sellar phase of the surgery was then performed by a neurosurgeon, who was responsible for the tumor removal. Once the neoplasm was resected, the endoscope was moved forward into the cavity, in order to identify tumor remnants in the recesses created by the descent of the suprasellar cistern. Sellar repair was of extended approaches or intraoperative cerebrospinal fluid (CSF) leakage by means of dural substitutes, surgicel®, gelfoam® or fibrin glue. Nasal packing was not routinely Patients were then monitored closely for tive complications, such as meningitis, epistaxis, pneumocephalus, CSF leakage, pneumonia and death. Strict measurement of urine output and urinary density were also carried out in
RESULTS
We identified eleven underwent ETSS for GH between January 2008 and September 2011. From this initial group, two patients had already undergone craniotomies before resecting the GH secreting pituitary adenoma, and were therefore excluded. Another patient was excluded because she had received pre with somatostatin analogues. The remaining eight patients were composed by seven males and one female, with a median age of 41,5 years (min:31, max: 57).
Among our cohort, pre IGF-I levels were 615,5 ng/mL (min: 555 ng/mL, max: 1281 ng/mL), while the median values for GH were 20,70 ng/mL (min: 3,13, max: > 40,00). No thyroid hormone or testosterone deficiencies were identified.
One patient suffered from hypocortisolism, which was treated with hydrocortisone, 25 mg per day. Hyperprolactinemia was evinced in two of our patients.
Only one patient exhibited visual field disturbances, which consisted of superior bitemporal hemianopia. On imaging, this patient was found to have a tumor with suprasellar extension.
Further comorbidities included hypertension (4/8), dyslipidemia (2/8), diabetes mellitus (2/8), and cardiovascular disease (1/8). No cases of obstructive sleep apnea or osteoarthritis were identified.
The eight patients underwent radiologic assessment of their lesion with CECT scan, and six had gadolinium-enhanced MRI in addition. Seven patients presented macroadenomas, while only one patient had a microadenoma of 4 x 5 mm.
From the seven macroadenomas, five cases exhibited extrasellar extension or invasion. The majority of the cases (5/7) exhibited local spread into the sphenoid sinus with focal perforation of the sellar floor, and 3/7evidenced extension into the cavernous sinus (Table 1) . We identified eleven patients who underwent ETSS for GH-secreting adenomas between January 2008 and September 2011. From this initial group, two patients had already undergone craniotomies before resecting the GHsecreting pituitary adenoma, and were therefore r patient was excluded because she had received pre-surgical medical treatment with somatostatin analogues. The remaining eight patients were composed by seven males and one female, with a median age of 41,5 years (min:31, Among our cohort, pre-operatory median I levels were 615,5 ng/mL (min: 555 ng/mL, max: 1281 ng/mL), while the median values for GH were 20,70 ng/mL (min: 3,13, max: > 40,00 eight patients underwent radiologic assessment of their lesion with CECT scan, and six enhanced MRI in addition. Seven patients presented macroadenomas, while only one patient had a microadenoma of 4 x 5 mm.
From the seven macroadenomas, five cases exhibited extrasellar extension or invasion. The majority of the cases (5/7) exhibited local spread into the sphenoid sinus with focal perforation of the sellar floor, and 3/7evidenced extension into inus (Table 1) . The median duration of the surgical procedure was 217.50 minutes (min: 150 minutes, max: 335 minutes), and the median hospital stay for all patients was 7days (min:5, max: 11). though the surgical procedures were not followed by significant complications, median hospital stay of 7 days was due to endocrine control patients live in remote areas where access to endocrine follow-up is limited, so it was interest to discharge these patients with optimal endocrine control.
Table 1. Modified Hardy classification for the extension of the GH Hospital Mexico, San Jose, Costa Rica by means of primary ETSS between years 2008
Another patient also achieved biochemical remission based on his endocrinological panels at three and six months post-surgery. These patients had a non-invasive macroadenoma and a microadenoma, respectively.
From the six patients who did not achieve biochemical remission, five underwent additional CECT imaging assessment within one year after surgery, in addition to the immediate post operative scans. None of the patients showed The median duration of the surgical (min: 150 minutes, max: 335 minutes), and the median hospital stay 7days (min:5, max: 11). Even though the surgical procedures were not followed by significant complications, median hospital stay of 7 days was due to endocrine control. Several patients live in remote areas where access to was in our best interest to discharge these patients with optimal Among the cohort, the median at three months after surgery were 633 ng/mL (min: 199 ng/mL, max: 1600 ng/mL), while the corresponding GH levels were 10,20 ng/mL (min:0,96 ng/mL, max: 16,60 ng/mL). At six months post-operatory, the patients presented median IGF-I levels of 626 ng/mL (min: 98 ng/mL, max: 1497 ng/mL), and GH levels of 8,21 ng/mL (min: 0,24 ng/mL, max: 17,50 ng/mL). patients, one did not have IGF three months after surgery; nevertheless, at six months, this patient met criteria for biochemical remission ( Table 2 ).
Table 1. Modified Hardy classification for the extension of the GH-secreting adenomas treated at Hospital Mexico, San Jose, Costa Rica by means of primary ETSS between years 2008
Another patient also achieved biochemical remission based on his endocrinological panels at surgery. These patients invasive macroadenoma and a patients who did not achieve ochemical remission, five underwent additional CECT imaging assessment within one year after surgery, in addition to the immediate postoperative scans. None of the patients showed persistence and/or recurrence of the adenoma in the imaging studies (Figure 1 ).
Five cases were raised to and approved by the Pharmacotherapy Committee of our and received somatostatin LAR® -Octreotide) 8 months after the surgery (min: 4 months, max: 18 months). The median random GH levels of these patients after receiving medical therapy were 4,46 ng/mL) and the Among the cohort, the median IGF-I levels at three months after surgery were 633 ng/mL max: 1600 ng/mL), while the corresponding GH levels were 10,20 ng/mL /mL, max: 16,60 ng/mL). At six operatory, the patients presented I levels of 626 ng/mL (min: 98 ng/mL, max: 1497 ng/mL), and GH levels of 8,21 ng/mL (min: 0,24 ng/mL, max: 17,50 ng/mL). From these patients, one did not have IGF-I and GH values, three months after surgery; nevertheless, at six months, this patient met criteria for biochemical Five cases were raised to and approved by the Pharmacotherapy Committee of our Institution, and received somatostatin analogues (Sandostatin 8 months after the surgery (min: 4 months, max: 18 months). The median random GH levels of these patients after receiving medical therapy were 0,82ng/mL (min: 0,34 max:
IGF-I ones were 370 ng/mL (min: 246 ng/mL, max: 617 ng/mL). Four patients achieved biochemical remission after the addition of the drug, whereas one remained with elevated GH and IGF-levels. 
Nº of cases Percentage (%)
621 0 II 24,50 2 0 III >40,00 3 E III 8,01 4 E III >40,00 5 0 III 14,80 6 E III >40,00 7 Microadenoma 3,13 8 0 0 16,90 Revista Médica de la Universidad de Costa Rica. Volumen 8, número 2
DISCUSSION
Because acromegaly is associated with three-fold higher morbidity and mortality average person, the goal of its treatment is to achieve normal GH and IGF-I levels. become the surgical treatment of choice at our institution because it offers improved visualization, preservation of sinonasal function, improvement in the resection of suprasellar and parasellar components of the adenoma, and reduction of hospital length of stay when compared to microscopic transsphenoidal transcranial techniques [4] [5] [6] . Furthermore, the improved visualization and identification of extrasellar components through the advancement of the endoscope into the tumor cavity leads to a greater extent of resection and safety cohort, gross total resection was achieved in all cases, and no evidence of residual tumor in post surgical imaging studies was found, which supports this notion.
On the other hand, the complications of ETSS are usually minor and include transient diabetes insipidus and CSF leak, with incidences comparable or inferior to those reporte microsurgical technique [8] [9] . Our data confirm the low morbidity and mortality of this surgical procedure, with only three cases of transient diabetes insipidus, and no other reported complications.
In spite of good surgical outcomes, disease control in acromegaly can be elusive. Several literature reports estimate that approximately 40 60% of macroadenomas, particularly those with extrasellar invasion, are not controlled by surgery alone [10] . One of the first studies performed in the United States for ETSS in GH adenomas reported 42% of post endocrinological remission in macroadenomas [11] . In this cohort, 41.7% of patients exhibited invasion of the cavernous sinus, and 29.2% had suprasellar tumor extension. These findings were reproduced by Gondim et al [12] in their retrospective analysis of 67 Brazilian patients, where they found that less than 45% of patients Because acromegaly is associated with higher morbidity and mortality than the the goal of its treatment is to I levels. ETSS has become the surgical treatment of choice at our institution because it offers improved sal function, improvement in the resection of suprasellar and parasellar components of the adenoma, and reduction of hospital length of stay when transsphenoidal and Furthermore, the tion and identification of extrasellar components through the advancement of the endoscope into the tumor cavity leads to a greater extent of resection and safety [7] . In our cohort, gross total resection was achieved in all dual tumor in postsurgical imaging studies was found, which On the other hand, the complications of ETSS are usually minor and include transient diabetes insipidus and CSF leak, with incidences comparable or inferior to those reported with the Our data confirm the low morbidity and mortality of this surgical procedure, with only three cases of transient diabetes insipidus, and no other reported In spite of good surgical outcomes, disease control in acromegaly can be elusive. Several literature reports estimate that approximately 40 -60% of macroadenomas, particularly those with extrasellar invasion, are not controlled by surgery
One of the first studies performed in ted States for ETSS in GH-secreting adenomas reported 42% of post-surgical endocrinological remission in macroadenomas [11] . In this cohort, 41.7% of patients exhibited invasion of the cavernous sinus, and 29.2% had findings were [12] in their retrospective analysis of 67 Brazilian patients, where they found that less than 45% of patients with sphenoid sinus invasion had biochemical control of their acromegaly after primary ETSS. Additionally, van Bunderen et al 30% of remission after primary ETSS in their cohort of 30 Dutch patients, the majority of which exhibited extrasellar exte macroadenoma. retrospective study of 60 American patie et al [14] found that more invasive adenomas were significantly less likely to achieve biochemical remission after ETSS than those limited to the sella turcica, while Campbell et al Hardy and Knosp grades were associated wit significantly lower remission rates.
The data obtained from our cohort coincide with these international observations. The majority of our patients with macroadenomas (5/7) presented tumors with extrasellar extension and sphenoid sinus erosion, which h demonstrated by numerous authors significantly reduce the likelihood of biochemical remission after surgery surprising that, in our cohort, those patients with smaller lesions (microadenoma and non macroadenoma) attained biochemical remission after primary surgical treatment, whereas those patients with invasive tumors failed to reach cure. Because of the size of our cohort and the recent foundation of the Endoscopic Skull Base Surgery Unit at our Center in 2008, our remission rates in invasive adenomas were
The proximity of vital vascular and brain structures is what typically makes these lesions more surgically challenging be elusive due todural tumor microf persistently hypersecrete visualized and resected during surgery These microfoci were likely the reason for persistently elevated GH levels seen in our patients in spite of gross total resection as seen in the post operative imaging studies.
Because of the latter, the Acromegaly Consensus Group treatment and involvement of a multidisciplinary with sphenoid sinus invasion had biochemical control of their acromegaly after primary ETSS. y, van Bunderen et al [13] reported only 30% of remission after primary ETSS in their cohort of 30 Dutch patients, the majority of which exhibited extrasellar extension of their macroadenoma.
Furthermore, in their retrospective study of 60 American patients, Jane et al [14] found that more invasive adenomas were significantly less likely to achieve biochemical remission after ETSS than those limited to the sella turcica, while Campbell et al [4] found that higher Hardy and Knosp grades were associated with significantly lower remission rates.
The data obtained from our cohort coincide with these international observations. The majority of our patients with macroadenomas tumors with extrasellar extension and sphenoid sinus erosion, which has been demonstrated by numerous authors [4, [12] [13] [14] [15] [16] to significantly reduce the likelihood of biochemical remission after surgery. It is therefore not at all surprising that, in our cohort, those patients with smaller lesions (microadenoma and non-invasive macroadenoma) attained biochemical remission after primary surgical treatment, whereas those patients with invasive tumors failed to reach cure. Because of the size of our cohort and the recent foundation of the Endoscopic Skull Base Surgery enter in 2008, our remission rates in were to be expected.
The proximity of vital vascular and brain structures is what typically makes these lesions more surgically challenging, but remission can also be elusive due todural tumor microfoci that persistently hypersecrete GH and are not readily visualized and resected during surgery [17] [18] . These microfoci were likely the reason for persistently elevated GH levels seen in our patients in spite of gross total resection as seen in the postoperative imaging studies.
Because of the latter, the Acromegaly recommends multimodal treatment and involvement of a multidisciplinary Revista electrónica publicada por el Departamento de Farmacología de la Escuela de Medicina de la Universidad de Costa Rica, 2060 San José, Costa Rica. ® All rights reserved. Licensed under a Creative Commons Unported License.
Contáctenos: rev.med.ucr@gmail.com team to treat invasive macroadenomas of the alternatives in the management of these patients is the use of pre-operative somatostatin analogues. Because these drugs can lead to normalized GH and IGF-I levels, as well as tumor shrinkage, it is thought that they could improve the likelihood of biochemical remission after a radical resection [20] . Several studies have confirmed these theoretical advantages [22-25], but they differ from one another in patient selection, class of somatostatin analogue used, duration of treatment, variables analyzed, and follow Therefore, there are no international, validated guidelines for the use of pre-surgical somatostatin analogues. Nevertheless, the Latin American panel of experts advocates for the use of first medical therapy as a viable alternative to surgery, particularly in patients with invasive adenomas [2] .
The main argument to support this recommendation is the prospective, multicenter study performed by Mercado et al [26] the efficacy of primary octreotide in a Latin American population, which provides more epidemiologically-relevant data for our region, according to their observations. The cost of medical treatment, however, is a major limiting factor in developing countries such as ours. Therefore, at our institution we perform surgical excision by means of ETSS, then assess the need for medical therapy in case of persistence or recurrence. This approach corresponds to the more traditional algorithms published [10, 17, 18] , and is acceptable because of the low morbidity and mortality associated to the surgical procedure at our Center. Nevertheless, it is important to point out that the majority of our patients present large, invasive tumors, and that surgery is not likely to provide endocrine remission by itself.
CONCLUSIONS
Optimization of the acromegaly protocols at our Institution is necessary. The team to treat invasive macroadenomas [19] . One of the alternatives in the management of these somatostatin Because these drugs can lead to I levels, as well as tumor shrinkage, it is thought that they could improve the likelihood of biochemical remission after a radical Several studies have confirmed 25], but they differ from one another in patient selection, class of somatostatin analogue used, duration of treatment, variables analyzed, and follow-up.
ernational, validated surgical somatostatin ues. Nevertheless, the Latin American panel of experts advocates for the use of first-line medical therapy as a viable alternative to surgery, vasive adenomas [2] .
The main argument to support this recommendation is the prospective, multicenter
[26] to assess the efficacy of primary octreotide in a Latin American population, which provides more relevant data for our region,
The cost of medical treatment, however, is a in developing countries such Therefore, at our institution we primarily perform surgical excision by means of ETSS, and then assess the need for medical therapy in case of This approach corresponds to the more traditional algorithms , and is acceptable because of associated to the Nevertheless, it that the majority of our patients present large, invasive tumors, and that surgery is not likely to provide endocrine Optimization of the acromegaly treatment nstitution is necessary. The inclusion of somatostatin analogues operative period as part of management of patients with invasive GH secreting macroadenomas, that our patients do not effects of raised IGF-I and GH levels. somatostatin analogues in the postoperative period as part of the routine management of patients with invasive GHsecreting macroadenomas, should be pursued, so that our patients do not suffer from the deleterious I and GH levels.
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Los artículos que se quieran publicar en la Revista serán evaluados por al menos dos revisores especialistas en el tema. Los revisores Los revisores serán nombrados por el Consejo Editorial y realizarán un análisis crítico y exhaustivo de los artículos. La evaluación será a el autor tampoco sabrá quienes son los revisores.
Si el artículo es aceptado con condiciones, el autor deberá realizar las mejoras solicitadas por los revisores y la Revista en un plazo al, o adjuntar cualquier material e información adicional que se le solicite para verificar la validez de las conclusiones y del estudio mismo. Si el autor no remite el material adicional solicitado o las correcciones, el artículo no será considerado para su publicación.
Si un dictamen es positivo y el otro negativo, se buscará tivo entonces se considerará su publicación.
